Adam Kopp Email & Phone Number

With over twenty five years of experience in market access, government & national accounts, and patient advocacy, I am a Senior Director National Accounts at Rhythm Pharmaceuticals, a biopharmaceutical company developing and commercializing therapies for rare neuroendocrine diseases. In this role, I lead the strategic planning and execution of national account initiatives, including product launch, contracting, reimbursement, policy development and access for Rhythm's rare disease product Imcivree (setmelanotide). I leverage my analytical skills and payer account relationship building to optimize market access opportunities, drive revenue growth, and enhance patient outcomes. Prior to joining Rhythm, I was a Director of Government Accounts at Zogenix (acquired by UCB), where I managed the public payer strategy, policy development and contracting for a novel drug for rare epileptic disorders. I also supported the patient advocacy and public policy functions, collaborating with internal and external stakeholders to advance the interests of the rare disease community. Before that, I was a Director of Government Accounts at Shire/Takeda, where I oversaw the managed markets strategy and execution for a portfolio of products in neuroscience, gastroenterology and rare disease. I am passionate about improving the lives of patients with rare and complex conditions, and I bring a diverse perspective and experience to the market access team at Rhythm.

Listed skills include Pharmaceutical Industry, Managed Care, Biotechnology, Pharmaceutical Sales, and 2 others.

• 

  Kent State University

  Business/Corporate Communications